Financhill
Back

Genmab AS Quote, Financials, Valuation and Earnings

Genmab AS Price Quote

$202.36
-0.12 (-0.06%)
(Updated: November 21, 2024 at 11:10 AM ET)

Genmab AS Key Stats

Sell
17
Genmab AS (GNMSF) is a Sell

Day range:
$200.96 - $209.92
52-week range:
$201.93 - $334.33
Dividend yield:
0%
P/E ratio:
21.99
P/S ratio:
4.76
P/B ratio:
2.8%

Volume:
552
Avg. volume:
10.7K
1-year change:
-38.27%
Market cap:
$13.4B
Revenue:
$2.4B
EPS:
$10.52

How Much Does Genmab AS Make?

  • How Much Are Genmab AS's Sales Annually?
    GNMSF Revenues are $2.4B
  • How Much Profit Does Genmab AS's Make A Year?
    GNMSF net income is $631.9M

Is Genmab AS Growing As A Company?

  • What Is Genmab AS's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.19%
  • What Is Genmab AS's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is -0.37%

Genmab AS Stock Price Performance

  • Did Genmab AS Stock Go Up Last Month?
    Genmab AS share price went down by -12.84% last month
  • Did GNMSF's Share Price Rise Over The Last Year?
    GNMSF share price fell by -38.27% over the past 1 year

What Is Genmab AS 52-Week High & Low?

  • What Is Genmab AS’s 52-Week High Share Price?
    Genmab AS has traded as high as $334.33 over the past 52 weeks
  • What Is Genmab AS’s 52-Week Low Share Price?
    Genmab AS has traded as low as $201.93 over the past 52 weeks

Genmab AS Price To Free Cash Flow

Is It Risky To Buy Genmab AS?

  • How Much Debt Does Genmab AS Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Genmab AS Have?
    Cash and short term investments quarterly total is $2.6B
  • What Is Genmab AS’s Book Value Per Share?
    Book value per share is 75.28

Is Genmab AS Cash Flow Positive?

  • What Is GNMSF Cash Flow From Operations?
    Cash flow from operations (TTM) is $983.5M
  • What Is Genmab AS’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$580.7M
  • What Is Genmab AS’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$1.5B

Genmab AS Return On Invested Capital

  • Is Management Doing A Good Job?
    GNMSF return on invested capital is 14.86%
  • What Is Genmab AS Return On Assets?
    ROA measures how assets are converting to revenues and is 12.66%
  • What Is GNMSF Return On Equity?
    ROE is a measure of profitability and is 14.86%

Genmab AS Earnings Date & Stock Price

  • What Is Genmab AS's Stock Price Today?
    A single share of GNMSF can be purchased today for 202.48
  • What Is Genmab AS’s Stock Symbol?
    Genmab AS trades on the otcm under the ticker symbol: GNMSF
  • When Is Genmab AS’s Next Earnings Date?
    The next quarterly earnings date for Genmab AS is scheduled on November 21, 2024
  • When Is GNMSF's next ex-dividend date?
    Genmab AS's next ex-dividend date is May 26, 2020
  • How To Buy Genmab AS Stock?
    You can buy Genmab AS shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

Genmab AS Competitors

  • Who Are Genmab AS's Competitors?
    Below is a list of companies who compete with Genmab AS or are related in some way:
    • Ascendis Pharma AS (ASND)
    • Evaxion Biotech AS (EVAX)
    • Galecto Inc (GLTO)
    • IO Biotech Inc (IOBT)

Genmab AS Dividend Yield

  • What Is GNMSF Dividend Yield?
    Genmab AS’s dividend yield currently is 0%
  • What Is Genmab AS’s Payout Ratio?
    Genmab AS’s payout ratio is 0%
  • When Did Genmab AS Last Pay A Dividend?
    The latest dividend pay date is November 21, 2024
  • What Is Genmab AS’s Dividend Per Share?
    Genmab AS pays a dividend of $0.00 per share

Genmab AS Analyst Estimates

YoY Growth Past Surprise
EPS: -37.41% 0%
Revenue: 18.65% -0.87%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 0.00
Downside from Last Price: -100%

Major Shareholders

  • How many GNMSF shares are owned by institutional investors?
    37.9M GNMSF shares are owned by institutional investors
  • How many GNMSF shares are owned by insiders?
    7M GNMSF shares are owned by insiders